Skip to main content
. 2022 Nov 10;2(11):1404–1417. doi: 10.1158/2767-9764.CRC-22-0266

FIGURE 1.

FIGURE 1

ZL-1201 is a differentiated anti-CD47 therapeutic antibody with improved hematologic safety profile. A, Scheme of ZL-1201 anti-CD47 mAb. B, Structure of 5F9 and ZL-1201 in complex with CD47. C, ZL-1201 comparably disrupts CD47–SIRPα signaling to the benchmark 5F9 analog in a dose-dependent manner. D,In vitro binding of isotype control, benchmark, and ZL-1201 with Raji cells in a dose-dependent manner. E, 5F9, ZL-1201-Fc-WT, and ZL-1201 comparative antitumor efficacy study in Raji tumor cell xenograft model. F, ZL-1201 and 5F9 comparative dose-dependent antitumor efficacy in Raji tumor cell xenograft model. G,In vitro phagocytosis of RBCs by MDMs with isotype control, benchmark, and ZL-1201 in a dose-dependent manner. H,In vitro phagocytosis of Raji cells by MDMs with benchmark, and ZL-1201 in a dose-dependent manner. The levels of hemoglobin (J), erythrocyte counts (K), and platelet counts (L) were measured in 28-day toxicology studies in cynomolgus monkeys treated with 30 mg/kg of ZL-1201 or benchmark IV (n = 3), once per week in the presence or absence of the 3 mg/kg priming dose. Data are presented as mean + SEM.